02172 微創腦科學
MICROPORT NEURO
MICROPORT NEURO
| Listing Date | 2022/07/15 |
| Listing Price | 24.640 |
Quote
Subscription Result
- Subscription Rate45.27x
- Guarantee One Lot Size25 lot
- One Lot Success Rate4.88%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
MicroPort NeuroTech is a China-based company in the neuro-interventional medical device industry. It amassed a total of 30 assets in its portfolio, including ten therapeutic products and three access products approved and commercialized in China and 17 product candidates under development.
Its therapeutic products covering all of the three major areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke (AIS).
The Group have commercialized products covering key therapeutic categories, including embolization coils, flowdiverting stents and stent grafts. In addition to approvals in China, NUMEN and NUMEN FR, two of flagship embolization coil products, have been approved in the United States, the European Union and South Korea. It plans to establish a R&D and production center in the United States.
According to CIC, the Group is the only Chinese company among the top five players in this market in terms of revenue in 2020, with a market share of approximately 4%.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 1000 |
GLOBAL OFFERING
| No. of Offer Shares | 13.70M shares |
| No. of International Offer Shares | 9.59M shares |
| No. of HK Offer Shares | 4.11M shares |
| Offer Price | $24.64 |
| Stock Code | 2172 |
| Sponsor(s) | J.P. Morgan Securities (Far East) Limited, China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | J.P. Morgan Securities (Asia Pacific) Limited, China International Capital Corporation Hong Kong Securities Limited, Futu Securities International (Hong Kong) Limited, Livermore Holdings Limited |
TIME TABLE
| Application Period | Jun 29 (Wed) - noon, Jul 08 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jul 14 (Thu) |
| Result Announcement Date | On or before Jul 14 (Thu) |
| Dealings in Shares commence on | Jul 15, 2022. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $24.64 |
| Capitalization | 14.36B |
| NAV / share ($) | $2.41 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 24.64, the net proceeds raised would be HKD 278.10M, of which |
| 30% : Research and development of therapeutic and access products |
| 20% : Commercialization of products |
| 15% : Expansion of manufacturing facility to increase production |
| 20% : Expanding global presence |
| 10% : Advancing product portfolio through strategic acquisitions and investment |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).